首页 > 最新文献

Drug metabolism and personalized therapy最新文献

英文 中文
CYP2C9 gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study. CYP2C9基因多态性对动脉性高血压患者氯沙坦降压效果和降糖效果的影响:一项观察性研究
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0115
Irina I Sinitsina, Alexey V Boyarko, Ilyas I Temirbulatov, Dmitry A Sychev, Kristina A Akmalova, Zhannet A Sozaeva, Elena A Grishina, Karin B Mirzaev, Anastasiia V Asoskova, Vladimir P Fisenko

Objectives: CYP2C9 gene polymorphic variants can decrease the effects of losartan, reducing active metabolite (E-3174) formation. Study aims to determine the influence of *2 (+430C>T; rs799853) and *3 (+1075A>C; rs1057910) CYP2C9 gene polymorphic variants on the hypotensive and uricosuric effect of losartan on patients with arterial hypertension.

Methods: Eighty one patients with stage 1-2 arterial hypertension newly diagnosed with ABMP were enrolled in the study. Physicians started losartan treatment and then we measured urine concentration of E-3174/losartan to estimate CYP2C9 activity. After 3-month losartan treatment we compared effectiveness of the therapy with ABPM and plasma uric acid level between carriers of CYP2C9 *1/*1 and CYP2C9 gene polymorphic variants (*2 and *3).

Results: Carriage of CYP2C9*2 and CYP2C9*3 alleles reduced the hypotensive effect of losartan (p<0.001, OR=8.13 (95% CI, 2.75-23.97)). Analysis of the ABPM data revealed that blood pressure was significantly higher in patients with polymorphic genotypes. There was no significant difference in uric acid level in plasma and losartan and its metabolite concentration in urine between genotypes.

Conclusions: Carriage of low function polymorphic variants of the CYP2C9 gene (*2 and *3) reduced the hypotensive effect of losartan according to ABPM and don't affect uric acid level in plasma and E-3174/losartan in urine.

目的:CYP2C9基因多态性变异可降低氯沙坦的作用,减少活性代谢物(E-3174)的形成。研究旨在确定*2 (+430C>T)的影响;rs799853)和*3 (+1075A>C;rs1057910) CYP2C9基因多态性变异对氯沙坦对高血压患者降压降尿作用的影响。方法:81例新诊断为ABMP的1-2期高血压患者入组研究。医生开始氯沙坦治疗,然后我们测量尿E-3174/氯沙坦浓度来估计CYP2C9活性。氯沙坦治疗3个月后,比较CYP2C9 *1/*1和CYP2C9基因多态性变异携带者(*2和*3)的ABPM和血浆尿酸水平。结果:携带CYP2C9*2和CYP2C9*3等位基因可降低氯沙坦的降压作用(p结论:携带CYP2C9基因*2和*3低功能多态性变异可根据ABPM降低氯沙坦的降压作用,但不影响血浆尿酸水平和尿E-3174/氯沙坦。
{"title":"<i>CYP2C9</i> gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study.","authors":"Irina I Sinitsina,&nbsp;Alexey V Boyarko,&nbsp;Ilyas I Temirbulatov,&nbsp;Dmitry A Sychev,&nbsp;Kristina A Akmalova,&nbsp;Zhannet A Sozaeva,&nbsp;Elena A Grishina,&nbsp;Karin B Mirzaev,&nbsp;Anastasiia V Asoskova,&nbsp;Vladimir P Fisenko","doi":"10.1515/dmpt-2022-0115","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0115","url":null,"abstract":"<p><strong>Objectives: </strong><i>CYP2C9</i> gene polymorphic variants can decrease the effects of losartan, reducing active metabolite (E-3174) formation. Study aims to determine the influence of <i>*2</i> (+430C>T; rs799853) and *3 (+1075A>C; rs1057910) <i>CYP2C9</i> gene polymorphic variants on the hypotensive and uricosuric effect of losartan on patients with arterial hypertension.</p><p><strong>Methods: </strong>Eighty one patients with stage 1-2 arterial hypertension newly diagnosed with ABMP were enrolled in the study. Physicians started losartan treatment and then we measured urine concentration of E-3174/losartan to estimate CYP2C9 activity. After 3-month losartan treatment we compared effectiveness of the therapy with ABPM and plasma uric acid level between carriers of <i>CYP2C9 *1/*1</i> and <i>CYP2C9</i> gene polymorphic variants (<i>*2</i> and <i>*3</i>).</p><p><strong>Results: </strong>Carriage of <i>CYP2C9*2</i> and <i>CYP2C9*3</i> alleles reduced the hypotensive effect of losartan (p<0.001, OR=8.13 (95% CI, 2.75-23.97)). Analysis of the ABPM data revealed that blood pressure was significantly higher in patients with polymorphic genotypes. There was no significant difference in uric acid level in plasma and losartan and its metabolite concentration in urine between genotypes.</p><p><strong>Conclusions: </strong>Carriage of low function polymorphic variants of the <i>CYP2C9</i> gene (<i>*2</i> and <i>*3</i>) reduced the hypotensive effect of losartan according to ABPM and don't affect uric acid level in plasma and E-3174/losartan in urine.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Pharmacogenetics and ethnicity: "Dr. José María Cantú" award announcement. 药物遗传学和种族:“Dr. josise María Cantú”奖公告。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2023-0037
Ingrid Fricke-Galindo, Adrián LLerena
{"title":"Pharmacogenetics and ethnicity: \"Dr. José María Cantú\" award announcement.","authors":"Ingrid Fricke-Galindo,&nbsp;Adrián LLerena","doi":"10.1515/dmpt-2023-0037","DOIUrl":"https://doi.org/10.1515/dmpt-2023-0037","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9683585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative assessment of antioxidant potential of selected homeopathic preparations in clinical practice. 顺势疗法制剂抗氧化能力的定量评价。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0169
Arun Kumar, Suneel Prajapati, Mahima Sharma, Tejveer Singh, Neha Choudhary, Alok C Bharti, Rohit Sharma, Pankaj Gupta

Objectives: Antioxidant property like radical scavenging is a primary target to elucidate the efficacy mechanism of a drug against diseases linked to oxidative stress such as cancer, metabolic disorders, rheumatoid arthritis, etc. In alternative therapies, homeopathy is one of the preferred choices by patients and clinicians due to its potential to cure chronic and complex illnesses. However, the efficacy of homeopathic preparations at high diluted potencies attracts rational criticism due to insufficient scientific knowledge supporting the mechanism of action. Therefore, an attempt was made to estimate the total phenolic content (TPC) and radical scavenging activity of clinically prescribed homeopathic drugs.

Methods: With gallic acid as a reference control, mother tinctures (MTs) and different potencies of Eucalyptus globulus (EG), Syzygium jambolanum (SJ), Ruta graveolens (RG), and Thuja occidentalis (TO) were used to perform Folin-Ciocalteu test, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays.

Results: The results showed TPC of MTs equivalent to µg/mL of gallic acid viz; EG (4,872.5 ± 133.2), SJ (8,840.5 ± 14.8), RG (985.6 ± 39.1), and TO (341.5 ± 19.5) with significant ABTS and DPPH radical scavenging potential. Whereas 30C and 200C potencies of each homeopathic drug showed undetectable phenolic content and insignificant radical scavenging potential compared to vehicle control, i.e., alcohol 90% (2.0 ± 1.5).

Conclusions: The reported efficacy of 30C and 200C potencies of homeopathic medicines against oxidative stress-related illnesses might be due to mechanisms other than radical scavenging. Furthermore, the assays studied can be helpful in drug standardization and quality control of MTs that are used as starting material in homeopathic preparations.

目的:自由基清除等抗氧化特性是阐明药物抗氧化应激相关疾病(如癌症、代谢紊乱、类风湿性关节炎等)疗效机制的主要靶点。在替代疗法中,顺势疗法是患者和临床医生的首选之一,因为它有治愈慢性和复杂疾病的潜力。然而,由于支持其作用机制的科学知识不足,高稀释效力的顺势疗法制剂的功效引起了理性的批评。因此,我们试图估计临床处方顺势疗法药物的总酚含量(TPC)和自由基清除活性。方法:以没食子酸为对照,分别用不同效价的蓝桉(EG)、白杨(SJ)、石竹(RG)、西叶桉(TO)母剂(MTs)进行福林- ciocalteu试验、2,2′-氮基-双(3-乙基苯并噻唑啉-6-磺酸)(ABTS)和2,2-二苯基-1-苦基肼(DPPH)测定。结果:MTs的TPC =µg/mL没食子酸viz;EG(4872.5±133.2),SJ(8840.5±14.8),RG(985.6±39.1)和TO(341.5±19.5)具有显著的ABTS和DPPH自由基清除潜力。然而,与对照剂(即酒精含量为90%(2.0±1.5))相比,每种顺势疗法药物在30C和200C时均未显示出可检测到的酚含量和微不足道的自由基清除潜力。结论:所报道的30℃和200℃的顺势疗法药物对氧化应激相关疾病的疗效可能是由于自由基清除以外的机制。此外,所研究的检测方法可用于顺势疗法制剂中作为起始原料的mt的药物标准化和质量控制。
{"title":"Quantitative assessment of antioxidant potential of selected homeopathic preparations in clinical practice.","authors":"Arun Kumar,&nbsp;Suneel Prajapati,&nbsp;Mahima Sharma,&nbsp;Tejveer Singh,&nbsp;Neha Choudhary,&nbsp;Alok C Bharti,&nbsp;Rohit Sharma,&nbsp;Pankaj Gupta","doi":"10.1515/dmpt-2022-0169","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0169","url":null,"abstract":"<p><strong>Objectives: </strong>Antioxidant property like radical scavenging is a primary target to elucidate the efficacy mechanism of a drug against diseases linked to oxidative stress such as cancer, metabolic disorders, rheumatoid arthritis, etc. In alternative therapies, homeopathy is one of the preferred choices by patients and clinicians due to its potential to cure chronic and complex illnesses. However, the efficacy of homeopathic preparations at high diluted potencies attracts rational criticism due to insufficient scientific knowledge supporting the mechanism of action. Therefore, an attempt was made to estimate the total phenolic content (TPC) and radical scavenging activity of clinically prescribed homeopathic drugs.</p><p><strong>Methods: </strong>With gallic acid as a reference control, mother tinctures (MTs) and different potencies of <i>Eucalyptus globulus</i> (EG), <i>Syzygium jambolanum</i> (SJ), <i>Ruta graveolens</i> (RG), and <i>Thuja occidentalis</i> (TO) were used to perform Folin-Ciocalteu test, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays.</p><p><strong>Results: </strong>The results showed TPC of MTs equivalent to µg/mL of gallic acid viz; EG (4,872.5 ± 133.2), SJ (8,840.5 ± 14.8), RG (985.6 ± 39.1), and TO (341.5 ± 19.5) with significant ABTS and DPPH radical scavenging potential. Whereas 30C and 200C potencies of each homeopathic drug showed undetectable phenolic content and insignificant radical scavenging potential compared to vehicle control, i.e., alcohol 90% (2.0 ± 1.5).</p><p><strong>Conclusions: </strong>The reported efficacy of 30C and 200C potencies of homeopathic medicines against oxidative stress-related illnesses might be due to mechanisms other than radical scavenging. Furthermore, the assays studied can be helpful in drug standardization and quality control of MTs that are used as starting material in homeopathic preparations.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma. CYP2D6*4、CYP2D6*10多态性对马酸替洛尔治疗青光眼患者安全性的影响
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0117
Larisa K Moshetova, Maria M Soshina, Ksenia I Turkina, Elena A Grishina, Zhannet A Sozaeva, Anastasia A Kachanova, Kristina A Akmalova, Dmitriy V Ivashchenko, Mikhail S Zastrozhin, Vladimir P Fisenko, Dmitry A Sychev

Objectives: Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver. The aim of this study was the evaluation of the influence of CYP2D6*4 and CYP2D6*10 gene polymorphisms on the safety of medications containing 0.5% of timolol maleate as glaucoma treatment in patients with primary open-angle glaucoma (POAG).

Methods: 105 patients with POAG were prescribed glaucoma medications, containing 0.5% timolol maleate. The safety of glaucoma treatment was determined by electrocardiography (ECG) (to assess heart rate (HR) and PQ interval) and blood pressure (BP) measurements. The real-time polymerase chain reaction method was used for the detection of single nucleotide polymorphisms (SNP).

Results: The risk of adverse drug reactions was higher in patients with the CYP2D6*4 GA genotype compared with GG: mean HR change at 1 month (2.88 ± 4.68 and 6.44 ± 5.57, p<0.001) and 6 months (5.14 ± 8.93 and 7.88 ± 5.65, p<0.001), mean PQ interval change at 1 (0.01 ± 0.031 and 0.02 ± 0.022, p=0.003) and 6 months (0.01 ± 0.032 and 0.02 ± 0.024, p=0.003). The risk of adverse drug reactions was higher in patients with the CYP2D6*10 CT genotype compared with CC: mean HR change at 1 month (2.94 ± 4.65 and 6.34 ± 5.66, p<0.001) and 6 months (5.20 ± 8.90 and 7.78 ± 5.75, p<0.001), mean PQ interval change at 1 (0.01 ± 0.032 and 0.02 ± 0.021, p=0.014) and 6 months (0.01 ± 0.033 and 0.02 ± 0.022, p=0.014).

Conclusions: CYP2D6*4 and CYP2D6*10 gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.

目的:马来酸替马洛尔用于青光眼的治疗,经肝脏细胞色素CYP2D6代谢。本研究旨在评价CYP2D6*4和CYP2D6*10基因多态性对含0.5%马酸替马洛尔治疗原发性开角型青光眼(POAG)患者青光眼安全性的影响。方法:105例POAG患者给予含0.5%马来酸噻洛尔的青光眼药物治疗。通过心电图(ECG)(评估心率(HR)和PQ间期)和血压(BP)测量来确定青光眼治疗的安全性。采用实时聚合酶链反应法检测单核苷酸多态性(SNP)。结果:药品不良反应的风险更高的患者CYP2D6 * 4 GA基因型与加贝:意味着人力资源变化在1个月(2.88±4.68,6.44±5.57,pCYP2D6 * 10 CT基因型与CC:意味着人力资源变化在1个月(2.94±4.65,6.34±5.66,pConclusions: CYP2D6 * 4和CYP2D6 * 10基因多态性可能影响的风险更高timolol-induced心动过缓和PQ间隔增加治疗的药物含有0.5%的马来酸timolol青光眼患者。
{"title":"Effect of <i>CYP2D6*4</i>, <i>CYP2D6*10</i> polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma.","authors":"Larisa K Moshetova,&nbsp;Maria M Soshina,&nbsp;Ksenia I Turkina,&nbsp;Elena A Grishina,&nbsp;Zhannet A Sozaeva,&nbsp;Anastasia A Kachanova,&nbsp;Kristina A Akmalova,&nbsp;Dmitriy V Ivashchenko,&nbsp;Mikhail S Zastrozhin,&nbsp;Vladimir P Fisenko,&nbsp;Dmitry A Sychev","doi":"10.1515/dmpt-2022-0117","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0117","url":null,"abstract":"<p><strong>Objectives: </strong>Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver. The aim of this study was the evaluation of the influence of <i>CYP2D6*4</i> and <i>CYP2D6*10</i> gene polymorphisms on the safety of medications containing 0.5% of timolol maleate as glaucoma treatment in patients with primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>105 patients with POAG were prescribed glaucoma medications, containing 0.5% timolol maleate. The safety of glaucoma treatment was determined by electrocardiography (ECG) (to assess heart rate (HR) and PQ interval) and blood pressure (BP) measurements. The real-time polymerase chain reaction method was used for the detection of single nucleotide polymorphisms (SNP).</p><p><strong>Results: </strong>The risk of adverse drug reactions was higher in patients with the <i>CYP2D6*4</i> GA genotype compared with GG: mean HR change at 1 month (2.88 ± 4.68 and 6.44 ± 5.57, p<0.001) and 6 months (5.14 ± 8.93 and 7.88 ± 5.65, p<0.001), mean PQ interval change at 1 (0.01 ± 0.031 and 0.02 ± 0.022, p=0.003) and 6 months (0.01 ± 0.032 and 0.02 ± 0.024, p=0.003). The risk of adverse drug reactions was higher in patients with the <i>CYP2D6*10</i> CT genotype compared with CC: mean HR change at 1 month (2.94 ± 4.65 and 6.34 ± 5.66, p<0.001) and 6 months (5.20 ± 8.90 and 7.78 ± 5.75, p<0.001), mean PQ interval change at 1 (0.01 ± 0.032 and 0.02 ± 0.021, p=0.014) and 6 months (0.01 ± 0.033 and 0.02 ± 0.022, p=0.014).</p><p><strong>Conclusions: </strong><i>CYP2D6*4</i> and <i>CYP2D6*10</i> gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9627638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies. 阿育吠陀草药抗衰老治疗的机制作用和潜力。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmdi-2023-0024
Kirti Raina, Ruchika Kumari, Palak Thakur, Rohit Sharma, Randeep Singh, Abhinay Thakur, Vikas Anand, Rohit Sharma, Ashun Chaudhary

Introduction: Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues.

Content: The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study.

Summary: The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging.

Outlook: This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.

药用植物和草药是阿育吠陀最重要的部分。《Charaka Samhita》中的罗萨耶那(Rasayana)一词赋予人长寿、年轻、强壮的身体、免于疾病,而罗萨耶那中提到的植物具有抗衰老的特性。衰老是一个集合术语,用于复杂的有害的生理变化,降低细胞的功能能力。氧化应激、端粒缩短、炎症和线粒体功能障碍是调节衰老过程的主要因素。时间衰老是一个不可逆的过程,但导致生物衰老的因素是可以控制的。阿育吠陀草药更适合治疗与年龄有关的问题。植物中有几种天然的生物活性物质可以延缓人类的衰老过程。它们触发诸如延长基因寿命和端粒酶活性、清除活性氧以及组织再生等行为。内容:阿育吠陀罗萨亚那中提到的植物具有抗衰老的潜力,可以用来解决与衰老有关的现代问题。本文介绍了一些阿育吠陀植物及其抗衰老潜力。本文综述了衰老的主要原因、药用植物及其作为潜在抗衰老介质的应用。衰老的过程仍然是一个谜。它是一个复杂的、不可挽回的动态过程,涉及许多因素,并受到一些环境和遗传影响。在临床试验中,Rasayana方面的研究还不多。衰老被认为是自由基损伤的结果。根据《查拉卡》,罗萨耶那药物打开部分或完全堵塞的通道。许多Rasayanas显示自由基清除活性,并有可能减轻衰老的影响。它概述了阿育吠陀药用植物作为灵感来源的重要性,以及这些植物作为抗衰老药物的使用。展望:本研究简要概述了衰老的原因,以及如何使用药用植物来逆转衰老过程。在本研究中,我们讨论了阿育吠陀草药的抗衰老潜力和机制作用。这些草药具有减缓自然衰老过程的特性,可以成功地解决常见的与年龄有关的问题。
{"title":"Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies.","authors":"Kirti Raina,&nbsp;Ruchika Kumari,&nbsp;Palak Thakur,&nbsp;Rohit Sharma,&nbsp;Randeep Singh,&nbsp;Abhinay Thakur,&nbsp;Vikas Anand,&nbsp;Rohit Sharma,&nbsp;Ashun Chaudhary","doi":"10.1515/dmdi-2023-0024","DOIUrl":"https://doi.org/10.1515/dmdi-2023-0024","url":null,"abstract":"<p><strong>Introduction: </strong>Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues.</p><p><strong>Content: </strong>The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study.</p><p><strong>Summary: </strong>The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging.</p><p><strong>Outlook: </strong>This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9918602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study. EPHX1 c.337的影响T>C和UGT2B7*2基因多态性对印度南部癫痫患者卡马西平维持剂量需求的横断面遗传关联研究
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0157
Shravan Venkatraman, Kesavan Ramasamy, Pradeep P Nair, Priyadharsini Rajendran

Objectives: Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a role in the requirement of CBZ maintenance dose. The aim was to study the influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy.

Methods: Persons with epilepsy (PWE) of both gender of age 15-65 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10% EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of EPHX1 c.337 T>C and UGT2B7*2, the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the genotypes and CBZ maintenance dose requirement for dominant and recessive models of EPHX1 c.337 T>C and UGT2B7*2. A value of p<0.05 was considered to be statistically significant.

Results: For UGT2B7*2 (rs 7439366), CT required a higher dose (CT 626 mg/day and TT 523 mg/day) but not found to be significant (p-value 0.167). PWE carrying CT genotype of EPHX1 c.337 T>C had 62 mg higher dose when compared to homozygous mutant CC (590 mg/day for CT and 528 mg/day for CC) but p-value was not found to be significant (p-value 0.835).

Conclusions: The results of our study done in 115 PWE showed there was a lack of association between SNPs of EPHX1 c.337 T>C, UGT2B7*2 and CBZ maintenance dose requirement in Southern part of India and this finding has to be confirmed in a larger sample size.

目的:卡马西平(CBZ)是一种用于局灶性癫痫发作的一线抗癫痫药物。血浆卡马西平水平表现出个体间的差异,遗传和非遗传因素对CBZ维持剂量的需求都有影响。目的是研究EPHX1 c.337的影响T>C和UGT2B7*2基因多态性对癫痫患者CBZ维持剂量需求的影响方法:选取年龄15 ~ 65岁、卡马西平单药治疗且服用相同维持剂量1年的男女癫痫患者(PWE)。静脉血5毫升,经10% EDTA处理,无菌处理。离心后,细胞组分用于DNA提取和基因分型。3个基因型的EPHX1 c.337T>C和UGT2B7*2,卡马西平平均剂量差异采用方差分析(ANOVA)。采用非配对t检验比较EPHX1 c.337显性和隐性模型的基因型和CBZ维持剂量需求T>C和UGT2B7*2。结果:对于UGT2B7*2 (rs 7439366), CT需要更高的剂量(CT 626 mg/天,TT 523 mg/天),但没有发现显著性(p值0.167)。携带EPHX1 c.337 CT基因型的PWE与纯合突变体CC相比,T>C的剂量增加了62 mg (CT为590 mg/d, CC为528 mg/d),但p值无显著性差异(p值为0.835)。结论:我们在115例PWE中进行的研究结果显示,EPHX1 c.337的snp之间缺乏关联T>C, UGT2B7*2和CBZ维持剂量需求在印度南部,这一发现需要在更大的样本量中得到证实。
{"title":"Influence of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i> genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study.","authors":"Shravan Venkatraman,&nbsp;Kesavan Ramasamy,&nbsp;Pradeep P Nair,&nbsp;Priyadharsini Rajendran","doi":"10.1515/dmpt-2022-0157","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0157","url":null,"abstract":"<p><strong>Objectives: </strong>Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a role in the requirement of CBZ maintenance dose. The aim was to study the influence of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i> genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy.</p><p><strong>Methods: </strong>Persons with epilepsy (PWE) of both gender of age 15-65 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10% EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i>, the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the genotypes and CBZ maintenance dose requirement for dominant and recessive models of <i>EPHX1 c.337 T>C</i> and <i>UGT2B7*2</i>. A value of p<0.05 was considered to be statistically significant.</p><p><strong>Results: </strong>For <i>UGT2B7*2</i> (rs 7439366), CT required a higher dose (CT 626 mg/day and TT 523 mg/day) but not found to be significant (p-value 0.167). PWE carrying CT genotype of <i>EPHX1</i> c.337 T>C had 62 mg higher dose when compared to homozygous mutant CC (590 mg/day for CT and 528 mg/day for CC) but p-value was not found to be significant (p-value 0.835).</p><p><strong>Conclusions: </strong>The results of our study done in 115 PWE showed there was a lack of association between SNPs of <i>EPHX1</i> c.337 T>C, <i>UGT2B7*2</i> and CBZ maintenance dose requirement in Southern part of India and this finding has to be confirmed in a larger sample size.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9985118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) - a randomized controlled trial. 评估乌纳尼药典制剂治疗皮肤病的疗效和安全性——一项随机对照试验。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0125
Saima Naseem, Mohammad Nawab, Syeda Hajra Fatima, Ahmed Minhajuddin, Asif Ahmad Khan

Objectives: The recent trends of rising unresponsive cases of dermatophytosis to conventional therapies pose a challenge in clinical practice. Unani medicine offers effective treatment for dermatophytosis. This study aimed to evaluate the efficacy and safety of the Unani herbo-mineral preparations Qurs-e-Asfar (QA) and Rogan-e-Narjeel (RN) in dermatophytosis.

Methods: This was a randomized, active-controlled and open-label clinical study. The participants diagnosed with dermatophytosis (n=78) randomized into treatment group (n=40) receiving oral QA (778 mg twice a day) and topical RN and control group (n=38) receiving oral Itraconazole (100 mg/day) and topical Terbinafine hydrochloride (1%) for 6 weeks.

Results: We found post-treatment improvement in itching by 86.3% vs. 78% (treatment vs. control group), erythema by 96.4% vs. 94.3%, scaling by 93% vs. 92.2% and peripheral raised margins by 82.3% vs. 81%. Furthermore, this study showed that the differences in the mean Total Signs and Symptoms Score (TSSS) and positive KOH mount were clinically and statistically significant (p<0.05) in both the groups. On comparing inter group, the differences in mean TSSS (p=0.07) and positive KOH mount (p=0.717) were found statistically insignificant.

Conclusions: This study concludes that the formulations QA and RN were effective and safe in the treatment of dermatophytosis.

目的:近年来,越来越多的皮肤癣患者对常规治疗无反应,这对临床实践提出了挑战。Unani药物对皮肤癣有有效的治疗。本研究旨在评价乌兰尼草药矿物制剂Qurs-e-Asfar (QA)和Rogan-e-Narjeel (RN)治疗皮肤真菌病的疗效和安全性。方法:这是一项随机、主动对照、开放标签的临床研究。诊断为皮肤癣的参与者(n=78)随机分为治疗组(n=40),接受口服QA (778 mg,每天2次)和外用RN,对照组(n=38)接受口服伊曲康唑(100 mg/天)和外用盐酸特比萘芬(1%),为期6周。结果:我们发现治疗后瘙痒改善率为86.3%对78%(治疗组对对照组),红斑改善率为96.4%对94.3%,结垢改善率为93%对92.2%,周围边缘升高率为82.3%对81%。此外,本研究显示,平均总体征和症状评分(TSSS)和阳性KOH含量的差异具有临床和统计学意义(p)结论:本研究认为QA和RN配方治疗皮肤癣是有效和安全的。
{"title":"Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) - a randomized controlled trial.","authors":"Saima Naseem,&nbsp;Mohammad Nawab,&nbsp;Syeda Hajra Fatima,&nbsp;Ahmed Minhajuddin,&nbsp;Asif Ahmad Khan","doi":"10.1515/dmpt-2022-0125","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0125","url":null,"abstract":"<p><strong>Objectives: </strong>The recent trends of rising unresponsive cases of dermatophytosis to conventional therapies pose a challenge in clinical practice. Unani medicine offers effective treatment for dermatophytosis. This study aimed to evaluate the efficacy and safety of the Unani herbo-mineral preparations Qurs-e-Asfar (QA) and Rogan-e-Narjeel (RN) in dermatophytosis.</p><p><strong>Methods: </strong>This was a randomized, active-controlled and open-label clinical study. The participants diagnosed with dermatophytosis (n=78) randomized into treatment group (n=40) receiving oral QA (778 mg twice a day) and topical RN and control group (n=38) receiving oral Itraconazole (100 mg/day) and topical Terbinafine hydrochloride (1%) for 6 weeks.</p><p><strong>Results: </strong>We found post-treatment improvement in itching by 86.3% vs. 78% (treatment vs. control group), erythema by 96.4% vs. 94.3%, scaling by 93% vs. 92.2% and peripheral raised margins by 82.3% vs. 81%. Furthermore, this study showed that the differences in the mean Total Signs and Symptoms Score (TSSS) and positive KOH mount were clinically and statistically significant (p<0.05) in both the groups. On comparing inter group, the differences in mean TSSS (p=0.07) and positive KOH mount (p=0.717) were found statistically insignificant.</p><p><strong>Conclusions: </strong>This study concludes that the formulations QA and RN were effective and safe in the treatment of dermatophytosis.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020. 厄瓜多尔Eugenio Espejo医院非小细胞肺癌患者的可行动突变2017-2020。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0112
Miguel Ángel Fernández Freire, Gabriela Isabel Gálvez Salazar, Mariana Meira Scudeler, Fernanda Rodrigues-Soares, Gabriela Fernanda Jaramillo Koupermann, Andrea Paola Moreno Ocampo

Objectives: Determine the frequency of actionable mutations in non-small cell lung cancer (NSCLC) and their correlation with overall survival (OS) and the site of metastases.

Methods: We performed a descriptive cross-sectional study at the Hospital de Especialidades Eugenio Espejo, Ecuador, between 2017 and 2020. Demographic, pathological, and molecular alterations in epidermal growth factor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), Programmed death-ligand 1 (PD-L1) expression, and clinical data detailed in patients' medical records with metastatic NSCLC were collected and analyzed. Seventy-nine stage IV patients had NSCLC; adenocarcinoma histology represents 56 (70.9%). The predominant mutation was in EGFR (22.8%); the most common variant was the deletion of exon 19 (72.2%). The most common metastatic site was in the contralateral lung (22.3%); however, this variable showed no significant correlation to the molecular markers (p=0.057). The overall survival (OS) and the status of molecular markers are not statistically significant (p=0.27). OS was better for non-mutated EGFR than for mutated EGFR (p=0.012). However, the frequency values are unrelated to contralateral lung metastasis or survival.

Conclusions: Our frequency mutations are concordant with those found in other studies in Latin America. EGFR was the most common biomarker mutation, and there was a better OS in EGFR non-mutated patient.

目的:确定非小细胞肺癌(NSCLC)中可操作突变的频率及其与总生存期(OS)和转移部位的相关性。方法:我们于2017年至2020年在厄瓜多尔Eugenio Espejo特别医院进行了一项描述性横断面研究。收集并分析转移性非小细胞肺癌患者病历中表皮生长因子(EGFR)、间变性淋巴瘤激酶(ALK)、ROS原癌基因1 (ROS1)、程序性死亡配体1 (PD-L1)表达的人口统计学、病理学和分子改变以及临床数据。79例IV期患者为NSCLC;腺癌组织学56例(70.9%)。显性突变为EGFR (22.8%);最常见的变异是外显子19的缺失(72.2%)。最常见的转移部位为对侧肺(22.3%);然而,该变量与分子标记无显著相关性(p=0.057)。两组总生存期(OS)和分子标记状态比较,差异无统计学意义(p=0.27)。非突变EGFR的OS优于突变EGFR (p=0.012)。然而,频率值与对侧肺转移或生存无关。结论:我们的突变频率与在拉丁美洲其他研究中发现的频率一致。EGFR是最常见的生物标志物突变,EGFR非突变患者的OS较好。
{"title":"Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020.","authors":"Miguel Ángel Fernández Freire,&nbsp;Gabriela Isabel Gálvez Salazar,&nbsp;Mariana Meira Scudeler,&nbsp;Fernanda Rodrigues-Soares,&nbsp;Gabriela Fernanda Jaramillo Koupermann,&nbsp;Andrea Paola Moreno Ocampo","doi":"10.1515/dmpt-2022-0112","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0112","url":null,"abstract":"<p><strong>Objectives: </strong>Determine the frequency of actionable mutations in non-small cell lung cancer (NSCLC) and their correlation with overall survival (OS) and the site of metastases.</p><p><strong>Methods: </strong>We performed a descriptive cross-sectional study at the Hospital de Especialidades Eugenio Espejo, Ecuador, between 2017 and 2020. Demographic, pathological, and molecular alterations in epidermal growth factor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), Programmed death-ligand 1 (PD-L1) expression, and clinical data detailed in patients' medical records with metastatic NSCLC were collected and analyzed. Seventy-nine stage IV patients had NSCLC; adenocarcinoma histology represents 56 (70.9%). The predominant mutation was in EGFR (22.8%); the most common variant was the deletion of exon 19 (72.2%). The most common metastatic site was in the contralateral lung (22.3%); however, this variable showed no significant correlation to the molecular markers (p=0.057). The overall survival (OS) and the status of molecular markers are not statistically significant (p=0.27). OS was better for non-mutated EGFR than for mutated EGFR (p=0.012). However, the frequency values are unrelated to contralateral lung metastasis or survival.</p><p><strong>Conclusions: </strong>Our frequency mutations are concordant with those found in other studies in Latin America. EGFR was the most common biomarker mutation, and there was a better OS in EGFR non-mutated patient.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A review of pharmacogenetic studies in the Bangladeshi population. 孟加拉国人群药物遗传学研究综述。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.1515/dmpt-2022-0194
Md Shaki Mostaid, Md Abdul Aziz, Jeba Atkia Maisha, Mohammad Safiqul Islam, Abdullah Al Maruf

Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (CYP2C9, VKORC1, and ITGB3), cancer drugs (TPMT, MTHFR, DPYD, ERCC1, GSTP1, XPC, XRCC1, TP53, XPD, and ABCC4), statins (COQ2, CYP2D6, and CYP3A5), and prednisolone (ABCB1, CYP3A5, and NR3C1) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh.

药物遗传学(PGx)指导处方是一种基于证据的精准医学策略。尽管在过去二十年中,PGx研究的质量和数量都取得了重大进展,但在孟加拉国这样的发展中国家却很少进行。本综述通过搜索PubMed和Google Scholar确定并总结了在孟加拉国人群中进行的PGx研究。此外,还对已确定的研究进行了质量评价。11项PGx研究确定了遗传变异对孟加拉国人群血液稀释剂(CYP2C9、VKORC1和ITGB3)、癌症药物(TPMT、MTHFR、DPYD、ERCC1、GSTP1、XPC、XRCC1、TP53、XPD和ABCC4)、他汀类药物(COQ2、CYP2D6和CYP3A5)和强的松龙(ABCB1、CYP3A5和NR3C1)的影响。大多数研究都是低到中等质量的。虽然已确定的研究表明了PGx检测的潜力,但孟加拉国人口中有限的PGx文献对在孟加拉国广泛实施PGx检测构成了重大挑战。
{"title":"A review of pharmacogenetic studies in the Bangladeshi population.","authors":"Md Shaki Mostaid,&nbsp;Md Abdul Aziz,&nbsp;Jeba Atkia Maisha,&nbsp;Mohammad Safiqul Islam,&nbsp;Abdullah Al Maruf","doi":"10.1515/dmpt-2022-0194","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0194","url":null,"abstract":"<p><p>Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (<i>CYP2C9</i>, <i>VKORC1</i>, and <i>ITGB3</i>), cancer drugs (<i>TPMT</i>, <i>MTHFR</i>, <i>DPYD</i>, <i>ERCC1</i>, <i>GSTP1</i>, <i>XPC</i>, <i>XRCC1</i>, <i>TP53</i>, <i>XPD</i>, and <i>ABCC4</i>), statins (<i>COQ2</i>, <i>CYP2D6</i>, and <i>CYP3A5</i>), and prednisolone (<i>ABCB1</i>, <i>CYP3A5</i>, and <i>NR3C1</i>) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10001778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies. 阿育吠陀草药作为抗衰老疗法的机制作用和潜力。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 eCollection Date: 2023-09-01 DOI: 10.1515/dmpt-2023-0024
Kirti Raina, Ruchika Kumari, Palak Thakur, Rohit Sharma, Randeep Singh, Abhinay Thakur, Vikas Anand, Rohit Sharma, Ashun Chaudhary

Introduction: Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues.

Content: The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study.

Summary: The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging.

Outlook: This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.

引言:药用植物和草药是阿育吠陀最重要的组成部分。Charaka Samhita中的Rasayana一词赋予了长寿、年轻、强壮的身体、免受疾病的侵袭,Rsayana中提到的植物具有抗衰老特性。衰老是指降低细胞功能能力的复杂有害生理变化的统称。氧化应激、端粒缩短、炎症和线粒体功能障碍是调节衰老过程的主要因素。时间老化是一个不可逆的过程,但导致生物老化的因素是可以控制的。阿育吠陀草药更适合治疗与年龄相关的问题。植物中存在几种天然生物活性剂,可以延缓人类的衰老过程。它们触发了增强基因寿命和端粒酶活性、清除ROS以及组织再生等作用。内容:阿育吠陀的Rasayana中提到的植物具有抗衰老的潜力,可以用来解决与衰老有关的现代问题。一些阿育吠陀植物及其抗衰老潜力已经在这篇综述中进行了解释。本研究涵盖了衰老的主要原因、药用植物及其作为潜在抗衰老介质的用途。摘要:衰老的过程仍然是个谜。这是一个复杂、不可恢复的动态过程,涉及许多因素,并受到许多环境和遗传影响。Rasayana方面尚未在临床试验中进行过多的研究。衰老被认为是自由基损伤的结果。根据Charaka的说法,Rasayana药物打开了部分或完全堵塞的通道。许多Rasayanas表现出清除自由基的活性,并有可能减轻衰老的影响。它概述了阿育吠陀药用植物作为灵感来源的重要性,以及这些植物作为抗衰老药物的用途。展望:这项研究简要展望了衰老的原因以及药用植物如何逆转衰老过程。在这项研究中,我们讨论了阿育吠陀草药的抗衰老潜力和机制作用。这些草药具有减缓自然衰老过程的特性,可以成功地解决常见的与年龄相关的问题。
{"title":"Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies.","authors":"Kirti Raina,&nbsp;Ruchika Kumari,&nbsp;Palak Thakur,&nbsp;Rohit Sharma,&nbsp;Randeep Singh,&nbsp;Abhinay Thakur,&nbsp;Vikas Anand,&nbsp;Rohit Sharma,&nbsp;Ashun Chaudhary","doi":"10.1515/dmpt-2023-0024","DOIUrl":"10.1515/dmpt-2023-0024","url":null,"abstract":"<p><strong>Introduction: </strong>Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues.</p><p><strong>Content: </strong>The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study.</p><p><strong>Summary: </strong>The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging.</p><p><strong>Outlook: </strong>This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10283473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug metabolism and personalized therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1